X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2409) 2409
Publication (298) 298
Book Chapter (38) 38
Book Review (31) 31
Magazine Article (2) 2
Book / eBook (1) 1
Conference Proceeding (1) 1
Data Set (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
hepatitis c virus (1317) 1317
index medicus (1261) 1261
hepatitis c (1177) 1177
direct-acting antivirals (1040) 1040
humans (989) 989
gastroenterology & hepatology (718) 718
antiviral agents - therapeutic use (698) 698
ribavirin (594) 594
antiviral agents (590) 590
hepatitis c, chronic - drug therapy (571) 571
hepatitis (552) 552
interferon (517) 517
sofosbuvir (478) 478
hcv (426) 426
male (403) 403
health aspects (402) 402
sustained virological response (402) 402
female (380) 380
infectious diseases (377) 377
hepacivirus - genetics (374) 374
middle aged (362) 362
genotype (357) 357
hepacivirus - drug effects (347) 347
cirrhosis (342) 342
therapy (330) 330
virus-infection (322) 322
infection (320) 320
drug therapy, combination (315) 315
treatment outcome (309) 309
direct-acting antiviral (307) 307
virus diseases (297) 297
direct-acting antiviral agents (294) 294
direct acting antivirals (286) 286
hepatitis c - drug therapy (277) 277
liver (276) 276
virology (256) 256
infections (253) 253
patients (253) 253
analysis (252) 252
adult (249) 249
care and treatment (246) 246
liver cirrhosis (244) 244
drug therapy (242) 242
biological response modifiers (239) 239
aged (233) 233
viruses (229) 229
genotype 1 infection (228) 228
sustained virologic response (217) 217
chronic hepatitis c (216) 216
hepatitis c, chronic - virology (211) 211
pharmacology & pharmacy (211) 211
digestive system diseases (189) 189
hiv (189) 189
hepatocellular carcinoma (186) 186
antiviral agents - adverse effects (185) 185
ribavirin - therapeutic use (184) 184
daclatasvir (182) 182
pegylated interferon (182) 182
antiviral agents - administration & dosage (177) 177
treatment-naive patients (177) 177
genotype 1 (172) 172
ledipasvir (171) 171
hcv infection (170) 170
protease inhibitors (169) 169
telaprevir (166) 166
immunology (163) 163
hepatitis-c virus (160) 160
antiviral agents - pharmacology (159) 159
hepatitis c, chronic - complications (159) 159
hepatology (159) 159
medical research (158) 158
genotypes (157) 157
prevalence (154) 154
plus ribavirin (152) 152
gastroenterology and hepatology (151) 151
efficacy (148) 148
genetic aspects (147) 147
liver transplantation (147) 147
medicine, experimental (146) 146
medicine & public health (142) 142
safety (140) 140
direct‐acting antivirals (138) 138
fibrosis (137) 137
hepatocellular-carcinoma (136) 136
genotype & phenotype (135) 135
microbiology (135) 135
risk factors (133) 133
chronic hepatitis-c (126) 126
epidemiology (125) 125
transplantation (124) 124
antiviral therapy (122) 122
medicine, general & internal (120) 120
boceprevir (119) 119
liver diseases (118) 118
simeprevir (117) 117
mortality (115) 115
review (115) 115
treatment-naive (115) 115
hepatitis c - virology (113) 113
recurrence (111) 111
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2256) 2256
Korean (62) 62
Spanish (44) 44
Hungarian (24) 24
Japanese (17) 17
French (16) 16
German (16) 16
Russian (8) 8
Chinese (2) 2
Italian (1) 1
Persian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Liver International, ISSN 1478-3223, 07/2017, Volume 37, Issue 7, pp. 974 - 981
Background & Aims The aim of this study was to assess the efficacy and safety of direct‐acting antivirals (DAA)‐based antiviral therapies for HCV patients with... 
direct‐acting antiviral | stage 4‐5 chronic kidney disease | hepatitis C virus infection | meta‐analysis | meta-analysis | direct-acting antiviral | stage 4-5 chronic kidney disease | ASUNAPREVIR | RENAL-DISEASE | COMBINATION | DIALYSIS PATIENTS | PEGYLATED INTERFERON | GENOTYPE 1 INFECTION | HEMODIALYSIS | DACLATASVIR | GASTROENTEROLOGY & HEPATOLOGY | Antiviral Agents - pharmacokinetics | Hepatitis C - drug therapy | Humans | Middle Aged | Hepacivirus - genetics | Male | Renal Insufficiency, Chronic - complications | Time Factors | Adult | Female | Hepatitis C - complications | Renal Insufficiency, Chronic - diagnosis | Drug Therapy, Combination | Odds Ratio | Kidney - physiopathology | Hepacivirus - drug effects | Severity of Illness Index | Antiviral Agents - therapeutic use | Genotype | Treatment Outcome | Renal Insufficiency, Chronic - physiopathology | Hepatitis C - diagnosis | Antiviral Agents - adverse effects | Hepatitis C - virology | Hepacivirus - growth & development | Aged | Sustained Virologic Response | Antiviral agents | Care and treatment | Chronic kidney failure | Hepatitis C virus | Health aspects | Analysis | Renal function | Ritonavir | Viruses | Disease control | Patients | Incidence | Confidence intervals | Hepatitis | Renal failure | Dialysis | Libraries | Kidney diseases | Safety | Hepatitis C | Kidney transplantation
Journal Article
Journal Article
European Journal of Gastroenterology & Hepatology, ISSN 0954-691X, 01/2019, Volume 31, Issue 1, pp. 75 - 79
Journal Article
HIV Medicine, ISSN 1464-2662, 04/2017, Volume 18, Issue 4, pp. 284 - 291
Journal Article
by Boerekamps, Anne and Newsum, Astrid M and Smit, Colette and Arends, Joop E and Richter, Clemens and Reiss, Peter and Rijnders, Bart J.A and Brinkman, Kees and Van Der Valk, Marc and Geerlings, S.E and Godfried, M.H and Goorhuis, A and Hovius, J.W and Van Der Meer, J.T.M and Kuijpers, T.W and Nellen, F.J.B and Van Der Poll, D.T and Prins, J.M and Van Vugt, H.J.M and Wiersinga, W.J and Wit, F.W.M.N and Van Duinen, M and Van Eden, J and Van Hes, A.M.H and Mutschelknauss, M and Nobel, H.E and Pijnappel, F.J.J and Weijsenfeld, A.M and Jurriaans, S and Back, N.K.T and Zaaijer, H.L and Berkhout, B and Cornelissen, M.T.E and Schinkel, C.J and Wolthers, K.C and Van Den Berge, M and Stegeman, A and Baas, S and Hage De Looff, L and Wintermans, B and Veenemans, J and Pronk, M.J.H and Ammerlaan, H.S.M and De Munnik, E.S and Jansz, A.R and Tjhie, J and Wegdam, M.C.A and Deiman, B and Scharnhorst, V and Van Eeden, A and Brokking, W and Groot, M and Elsenburg, L.J.M and Damen, M and Kwa, I.S and Van Kasteren, M.E.E and Brouwer, A.E and Van Erve, R and De Kruijf-Van De Wiel, B.A.F.M and Keelan-Pfaf, S and Van Der Ven, B and De Kruijf-Van De Wiel, B.A.F.M and Van Der Ven, B and Buiting, A.G.M and Kabel, P.J and Versteeg, D and Van Der Ende, M.E and Bax, H.I and Van Gorp, E.C.M and Nouwen, J.L and Schurink, C.A.M and Verbon, A and De Vries-Sluijs, T.E.M.S and De Jong-Peltenburg, N.C and Bassant, N and Van Beek, J.E.A and Vriesde, M and Van Zonneveld, L.M and Van Den Berg-Cameron, H.J and De Groot, J and De Zeeuw-De Man, M and Boucher, C.A.B and Koopmans, M.P.G and Van Kampen, J.J.A and Pas, S.D and Branger, J and Rijkeboer-Mes, A and Duijf-Van De Ven, C.J.H.M and Schippers, E.F and Van Nieuwkoop, C and Van IJperen, J.M and Geilings, J and Van Der Hut, G and Van Burgel, N.D and Leyten, E.M.S and Gelinck, L.B.S and Van Hartingsveld, A.Y and Meerkerk, C and Wildenbeest, G.S and Heikens, E and ... and Netherlands ATHENA HIV Observation and NVHB-SHM Hepatitis Working Grp and NVHB-SHM Hepatitis Working Group and the Netherlands ATHENA HIV Observational Cohort
Clinical Infectious Diseases, ISSN 1058-4838, 05/2018, Volume 66, Issue 9, pp. 1352 - 1359
Background. The Netherlands has provided unrestricted access to direct-acting antivirals (DAAs) since November 2015. We analyzed the nationwide hepatitis C... 
Treatment uptake | HIV/HCV coinfection | Direct-acting antivirals | treatment uptake | INFECTIOUS DISEASES | EFFICACY | SAFETY | SEX | MICROBIOLOGY | IMMUNOLOGY | direct-acting antivirals | INDIVIDUALS | HIV | REINFECTION | MEN | INFECTION | COHORT | AMSTERDAM
Journal Article
Medicinal Research Reviews, ISSN 0198-6325, 05/2019, Volume 39, Issue 3, pp. 860 - 886
Journal Article
Gastroenterology, ISSN 0016-5085, 2017, Volume 152, Issue 6, pp. 1578 - 1587
Journal Article